• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Agarwal on HRQoL and PROs with apalutamide in mCSPC


Neeraj Agarwal, MD, a professor of Medicine at the Huntsman Cancer Institute, University of Utah, discusses health-related quality of life (HRQoL) and patient-reported outcomes from the phase 3 TITAN trial of apalutamide (Erleada) in patients with metastatic castration-sensitive prostate cancer (mCSPC).

The TITAN trial (NCT02489318) randomized 1052 patients with mCSPC in a 1:1 ratio to receive apalutamide plus androgen-deprivation therapy (ADT) or placebo plus ADT. The results showed that adding apalutamide to ADT reduced the risk of death by 35% versus ADT alone.

Based on the efficacy and safety data from the primary TITAN analysis, the FDA approved apalutamide for the treatment of patients with mCSPC.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.